Hawkins Jonathan 4
4 · Augmedix, Inc. · Filed Oct 7, 2020
Insider Transaction Report
Form 4
Augmedix, Inc.NONE
Hawkins Jonathan
Chief Revenue Officer
Transactions
- Award
Employee Stock Option (right to buy)
2020-10-05+88,381→ 88,381 totalExercise: $0.65Exp: 2030-06-03→ Common Stock (88,381 underlying) - Award
Employee Stock Option (right to buy)
2020-10-05+86,697→ 86,697 totalExercise: $0.86Exp: 2029-04-18→ Common Stock (86,697 underlying)
Footnotes (3)
- [F1]The options vested as to 1/4 of the total shares on April 8, 2020, and an additional 1/48 of the options will vest monthly thereafter until the options are fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F2]On October 5, 2020, the Issuer's wholly-owned subsidiary, August Acquisition Corp. ("Acquisition Sub"), merged with and into Augmedix, Inc., a privately held Delaware corporation ("Augmedix"). Pursuant to this transaction (the "Merger"), Augmedix was the surviving corporation and became the Issuer's wholly owned subsidiary. All of the outstanding shares of stock of Augmedix held by accredited investors were converted into shares of the Issuer's common stock. All of the outstanding warrants, options and stock appreciation rights of Augmedix were assumed by the Issuer.
- [F3]The options vested as to 1/48 of the total shares on May 8, 2019, and an additional 1/48 of the options will vest monthly thereafter until the options are fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.